微创心通-B(02160.HK) 公布,至今,集团VitaFow系列经导管主动脉瓣膜及输送系统“TAVI”已进入全球35个国家及地区,累计植入量近1,300例。其中,2025年植入量预计将超过850例,较2024年增长近350%。2025年下半年,受惠VitaFow Liberty获得CE证后在欧洲国家商业化,以及在亚洲和拉美新兴市场国家份额的持续提升,植入量较上半年增长超过170%。(de/d)...
Source Link微创心通-B(02160.HK) 公布,至今,集团VitaFow系列经导管主动脉瓣膜及输送系统“TAVI”已进入全球35个国家及地区,累计植入量近1,300例。其中,2025年植入量预计将超过850例,较2024年增长近350%。2025年下半年,受惠VitaFow Liberty获得CE证后在欧洲国家商业化,以及在亚洲和拉美新兴市场国家份额的持续提升,植入量较上半年增长超过170%。(de/d)...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.